A chronic disease becomes treatable: First drug against hepatitis D approved

Prof. Dr. Stephan Urban (left) and Prof. Dr. Ralf Bartenschlager from the Department of Molecular Virology at the Centre for Infectiology at the UKHD have been working for years to improve the diagnosis and therapy of hepatitis virus infections.

What started as basic research around 25 years ago has now led to the successful approval of a drug: Hepcludex has been approved by the European Commission for the treatment of chronic hepatitis D infections.

This is a successful example of translation from basic research to application in Heidelberg.

Complete News (in German).

Recent Posts

See All


BioRN Network e.V.

Im Neuenheimer Feld 582

D-69120 Heidelberg

Contact us >>


BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations, supporting a rich translational ecosystem and promoting, representing and connecting the regional innovation stakeholders.

  • LinkedIn Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon

"Making Life Science matter...

...and Innovation happen!"


© Copyright - BioRN Network e.V. -  Imprint & Legal Notice - Data Privacy Policy